'India's Top-Selling Insulin Isn't Going Away, 10% Users To Be Impacted': Novo Nordisk India MD
Vikrant Shrotriya said Human Mixtard is not being discontinued in India and will be supplied in vial presentation
In a big relief for Indian patients, Denmark-based Novo Nordisk said it is not discontinuing India's largest-selling insulin brand, Human Mixtard.
In recent weeks, concerns had been growing among diabetes patients over reports of a possible discontinuation of Human Mixtard. However, the largest-selling insulin brand will remain available in vials and not pens.
In an interview, Vikrant Shrotriya, Managing Director, Novo Nordisk India, told News18, 'Novo Nordisk India confirms that it is not discontinuing Human Mixtard in India and will continue to supply it in vial presentation along with other human insulins, including Human Actrapid and Human Insulatard."
The company's decision aligns with its global strategy. Globally, the Danish drug-maker is gradually winding up production of human insulin pens as it focuses on ramping up manufacturing of its latest and popular obesity or diabetes injections, including the blockbuster drug, Ozempic.
'In India, we will be phasing out human insulin in Penfill and FlexPen gradually by the end of this year. However, we continue to remain a very strong player with the largest insulin formulation offerings in India in all three generations, including human insulin, modern insulin and new generation insulin."
Shrotriya explained that as part of the global portfolio consolidation, Novo Nordisk has decided to phase out certain insulin products or devices, 'which reflects our ongoing efforts to continually improve our existing product offerings and to ensure that maximum patients have access to the most effective and innovative treatments available, globally".
'This will create space needed in our global manufacturing network, rationalise and make it sustainable in the long run to bring efficiency in Novo Nordisk product offerings."
Despite the price control, according to Pharmarack data, Mixtard was the eleventh most-selling brand in India in April, with its moving annual turnover (MAT) standing at Rs 766 crore. The second-largest insulin brand also comes from Novo Nordisk's portfolio, Ryzodeg, with a MAT of Rs 593 crore, followed by Sanofi's Lantus.
Why is human insulin no longer a priority?
In high-income countries or even in India, for those who can afford it, most people with diabetes now rely on modern insulin, as this kind of product offers more precise blood sugar control and greater flexibility in dosing.
However, in low- and middle-income countries or for people who want cheaper options, human insulin remains the more widely used option. It's significantly cheaper and easier to produce. However, it doesn't always provide the same level of control or convenience which can be achieved by the latest insulin options.
Who will be impacted & what are the options?
The company believes that 'of the overall patients on insulin in India, only 10 per cent are impacted," with this decision to phase out penfill and flexpen versions.
'They will have the choice of transitioning to modern and new generation insulin or continue human insulin through vials or other treatment options available in the market, based on the recommendation from their physician," Shrotriya said, adding that 'the remaining 90 per cent of patients using insulin remain unimpacted".
'We continue our unwavering commitment towards people with diabetes by continuing to serve every 'one in two' patients in India who require insulin," he said. 'Accordingly, we are doing everything we can to liaise early with health authorities, support healthcare professionals, trade partners and patients in the transition to other treatment options."
Currently, Novo Nordisk claims that it is the only company in India offering three generations of insulins to patients living with diabetes.
Will continue to invest in R&D
On being asked if this withdrawal will affect their overall insulin portfolio and research and development plans in India, Shrotriya explained that 'Novo Nordisk India contributes around 10 per cent to more than 40 global trials across therapy areas".
'We continue to invest in R&D to bring more innovations for the benefit of people living with serious chronic diseases, including improved insulins such as glucose-sensitive insulin, beta-cell replacement therapies and once-weekly insulin therapy."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
18 minutes ago
- Mint
3,00,000 jobs at risk? Experts say THESE sectors likely to get impacted due to Trump tariffs on India
There are concerns among experts that increased tariffs announced by President Donald Trump on Indian imports into the United States, will have a negative impact on jobs in the affected sectors, PTI reported. According RP Yadav, founder and CMD of workforce solutions and HR services provider Genius HRTech, the hiked US tariffs are expected to significantly impact India's employment landscape in industries heavily dependent on the US market for growth and continuity. Sectors such as agriculture, auto components, gems and jewellery, and textiles are likely to be among the worst impacted, as per Yadav. He added that even within these sectors, it is the micro, small and medium enterprises (MSMEs) who will bear the brunt. Yadav estimates that between 2,00,000 to 3,00,000 jobs are at immediate risk. Further, the labour-intensive textiles industry alone could potentially lose 1,00,000 jobs, if the tariff regime continues beyond the next six months, he added. He added that in the gem and jewellery sector, including units in Surat and SEEPZ in Mumbai, 'thousands of jobs are at risk due to reduced demand and cost escalation in the US market', he added. However, not all agree. Balasubramanian Anantha Narayanan, Senior VP at TeamLease Services, feels that unlike China, India is largely a domestic consumption driven economy. Thus, any impact from the US tariffs would not impact jobs. 'At this point in time, we aren't seeing any signs of a slowdown or loss of jobs. This also by extension means that our jobs are largely in service of domestic demand too, with the exception of some sectors like ITeS among others,' Narayanan said. He added, 'Our exports to the USA are $87 billion, which is roughly about 2.2 per cent of our overall GDP. Largely pharma, electronics etc. won't be affected for now, which will further limit the export exposure to industries such as textiles, gems and jewellery among others.' Further, Narayanan noted that the full 50 per cent tariff hike comes into effect later this month on August 27, and it is possible that some negotiations could happen before that. He added that positives from the recently announced free trade agreement (FTA) with the UK and other countries, could possibly make way for the redirection of Indian goods, rather than a complete shut down of the exports. 'Even if these US tariffs do come about, we'll definitely figure out a way of redirecting or diversifying our trade to other markets. Therefore, at this point in time, we aren't seeing any signs of a slowdown or loss of jobs. It's an evolving situation and we'll get to know more in due course of time,' he feels. Aditya Mishra, MD and CEO of CIEL HR also feels that while the US tariff scenario is unsettling for Indian exporters, especially those in the auto components, electronics, engineering goods, footwear, gems and jewellery, leather, shrimp, and textiles, widespread layoffs appear unlikely at this stage. 'Companies are already in cost-containment mode, reducing discretionary spending, streamlining production, and freezing hiring. The immediate pressure will be on temporary and contract roles, particularly shop-floor workers, artisans, sales and logistics staff, and some mid-level managers in export-led units. This will have a cascading effect on thousands of MSMEs in the supply chain, which collectively account for a large share of employment,' Mishra felt.
News18
27 minutes ago
- News18
Air India cancels Milan-Delhi flight due to maintenance issue
Agency: Mumbai, Aug 17 (PTI) Tata Group-owned private carrier Air India on Sunday said it cancelled its Milan-Delhi flight of August 16 after detecting a maintenance issue at the last minute. Alternative arrangements are being made to fly the passengers to their destination at the earliest, Air India said in a statement. 'Flight AI138 operating from Milan to Delhi on August 16 was cancelled due to a maintenance task identified during pushback," the statement said. 'Our ground team in Milan extended immediate assistance to all the affected passengers, providing hotel accommodation and offering full refunds on cancellation or complimentary rescheduling as opted by the passengers," it said. According to Air India, along with the maintenance issue, the operating crew of the flight come under the mandatory flight duty-time limitation norms. Air India generally operates its Boeing 787-8/9 aircraft fleet to cater to European destinations. The airline, which came under private hands in January 2022, has, of late, been delaying, cancelling some flights at the last minute due to technical and maintenance issues. This is despite airline CEO and Managing Director Campbell Wilson repeatedly claiming that Air India has carried out comprehensive checks on its Boeing 787 aircraft fleet. A Delhi-bound Air India flight from Bhubaneswar was cancelled just prior to its departure on August 3 due to high cabin temperature. On July 31, an Air India Boeing 787-9 aircraft flying to London had to abort take-off at Delhi airport and return to the bay due to a technical issue. In a message to the customers recently, while listing out the various steps taken after the fatal crash of an AI-171 flight to London soon after take-off from the Ahmedabad airport, Wilson said detailed inspections of its Boeing 787-8 and 787-9 aircraft were done and 'no issues were found during inspection". PTI IAS ARI view comments First Published: August 17, 2025, 23:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
33 minutes ago
- Time of India
Paint sector slowdown: Early monsoon and price wars hit June quarter earnings, companies eye festive revival
The June quarter turned out to be a muted one for India's leading paint makers, as the early arrival of the monsoon and aggressive pricing by new entrants ate into their growth. Asian Paints, Berger Paints, Kansai Nerolac Paints and Akzo Nobel India all reported subdued numbers, though sequential improvement was visible in urban markets and realisations improved due to price hikes. Early monsoon dampens demand Asian Paints Managing Director and CEO Amit Syngle said the business saw a sharp impact from the unexpected onset of rains. 'In April and May, the demand was better, but it was strongly impacted by the early monsoon. However, I think the silver lining was that we saw some shoots of demand coming up in urban areas, which were down, and we hope that it continues as we go ahead,' Syngle said, quoted PTI. The company reported a 1.19 per cent dip in standalone sales revenue to Rs 7,848.83 crore. Its volume growth stood at 3.9 per cent year-on-year, but value fell 1.2 per cent. Berger Paints CEO Abhijit Roy too pointed to the 'heavier than expected monsoon towards the end of May and June,' which he said moderated growth. The company posted an 11 per cent fall in consolidated net profit at Rs 315 crore, while revenue from operations rose 3.55 per cent to Rs 3,200.76 crore. Competition squeezes margins Alongside the weather, intensifying market rivalry weighed heavily. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Could This NEW Collagen Blend Finally Reduce Your Cellulite? Vitauthority Learn More Undo 'The overall competition in the market is intense, with a lot of new competition coming in,' said Syngle, pointing to aggressive new players challenging incumbents in the decorative paints segment. Kansai Nerolac's Managing Director Pravin Chaudhari also highlighted the pressure. 'Overall, monsoon in many places has caused some disturbances that have led to temporary stoppages, especially in projects as well as some part of retail,' he said. The company reported a 4.12 per cent drop in consolidated net profit to Rs 215.6 crore, while revenue rose 1.35 per cent to Rs 2,162.03 crore. Akzo Nobel India, which reported a 20.6 per cent decline in net profit to Rs 91 crore, described the quarter as 'stressed' due to muted consumer sentiment and competitive intensity. CMD Rajiv Rajgopal said revenue growth across top players remained 'pretty flattish.' Paint makers are betting on the festive season to drive a turnaround. With Diwali coming earlier than last year, companies expect demand in August and September to improve. 'Construction activity based on whatever we saw in the month of June, we believe that Q2 should be better as far as decorative is concerned,' Chaudhari added. The Rs 75,000-crore Indian paint industry remains dominated by Asian Paints, with Berger, Kansai Nerolac, Akzo Nobel, Indigo Paints, Shalimar Paints and Nippon Paints also vying for market share. Stay informed with the latest business news, updates on bank holidays , public holidays , current gold rate and silver price .
